GSKVX000000070250

GSKVX000000070250 is an experimental quadrivalent influenza vaccine (qIVc) developed by GSK. It is produced using a cell-culture-based manufacturing process, which serves as an alternative to traditional egg-based production methods. By utilizing mammalian cell lines for viral propagation, the vaccine aims to avoid egg-adaptive mutations that can occur in the hemagglutinin protein, particularly in the A/H3N2 strain, which often lead to reduced vaccine effectiveness. The vaccine is designed to provide protection against four seasonal influenza strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). GSKVX000000070250 has been evaluated in Phase 1 and Phase 2 clinical trials to assess its safety, reactogenicity, and immunogenicity compared to licensed egg-based quadrivalent vaccines. While GSK has recently shifted its primary influenza pipeline focus toward mRNA-based technologies, GSKVX000000070250 represents a significant effort in their cell-derived vaccine portfolio.

Other names

qIVccell-derived quadrivalent influenza vaccineGSK cell-culture influenza vaccine